CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells
Open Access
Abstract
Chimeric antigen receptor (CAR)-modified T cells brought a paradigm shift in the treatment of chemotherapy-resistant lymphomas. Conversely, clinical experience with CAR T cells targeting solid tumors has been disheartening, indicating the necessity of their molecular-level optimization. While incorporating CD28 or 41BB costimulatory domains into CARs in addition to the CD3z signaling domain improved the long-term efficacy of T cell products, their influence on early tumor engagement has yet to be elucidated. We studied the antigen-independent self-association and membrane diffusion kinetics of first- (.z), second- (CD28.z, 41BB.z), and third- (CD28.41BB.z) generation HER2-specific CARs in the resting T cell membrane using super-resolution AiryScan microscopy and fluorescence correlation spectroscopy, in correlation with RoseTTAFold-based structure prediction and assessment of oligomerization in native Western blot. While .z and CD28.z CARs formed large, high-density submicron clusters of dimers, 41BB-containing CARs formed higher oligomers that assembled into smaller but more numerous membrane clusters. The first-, second-, and third-generation CARs showed progressively increasing lateral diffusion as the distance of their CD3z domain from the membrane plane increased. Confocal microscopy analysis of immunological synapses showed that both small clusters of highly mobile CD28.41BB.z and large clusters of less mobile .z CAR induced more efficient CD3ζ and pLck phosphorylation than CD28.z or 41BB.z CARs of intermediate mobility. However, electric cell-substrate impedance sensing revealed that the CD28.41BB.z CAR performs worst in sequential short-term elimination of adherent tumor cells, while the .z CAR is superior to all others. We conclude that the molecular structure, membrane organization, and mobility of CARs are critical design parameters that can predict the development of an effective immune synapse. Therefore, they need to be taken into account alongside the long-term biological effects of costimulatory domains to achieve an optimal therapeutic effect.Keywords
Funding Information
- National Research, Development and Innovation Office, Hungary (OTKA K119690, K143771, FK132773, GINOP-2.3.2-15-2016-00044, ÚNKP-21-5-DE-482, ÚNKP-22-3-II)
- European Regional Development Fund (OTKA K119690, K143771, FK132773, GINOP-2.3.2-15-2016-00044, ÚNKP-21-5-DE-482, ÚNKP-22-3-II)
- János Bolyai Research Scholarship of the Hungarian Academy of Sciences (OTKA K119690, K143771, FK132773, GINOP-2.3.2-15-2016-00044, ÚNKP-21-5-DE-482, ÚNKP-22-3-II)
- New National Excellence Program of the Ministry for Innovation and Technology (OTKA K119690, K143771, FK132773, GINOP-2.3.2-15-2016-00044, ÚNKP-21-5-DE-482, ÚNKP-22-3-II)
- National Research, Development and Innovation Fund (OTKA K119690, K143771, FK132773, GINOP-2.3.2-15-2016-00044, ÚNKP-21-5-DE-482, ÚNKP-22-3-II)
This publication has 32 references indexed in Scilit:
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen ReceptorJournal of Clinical Oncology, 2015
- lDDT: a local superposition-free score for comparing protein structures and models using distance difference testsBioinformatics, 2013
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- The CD3 ζ Subunit Contains a Phosphoinositide-Binding Motif That Is Required for the Stable Accumulation of TCR–CD3 Complex at the Immunological SynapseThe Journal of Immunology, 2011
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor EradicationMolecular Therapy, 2010
- Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T CellsCancer Research, 2007
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptorNature Biotechnology, 2002
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.Proceedings of the National Academy of Sciences, 1993